不同类型肾脏替代治疗方式对危重症患者的生存率有何影响？关注甲磺酸萘莫司他在 AN69 膜上的吸附作用。
How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes.
机构信息
Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, No. 180, Fenglin Rd, 200032, Shanghai, China.
Baxter Healthcare Corporation, Deerfield, IL, US.
出版信息
BMC Nephrol. 2024 Sep 20;25(1):314. doi: 10.1186/s12882-024-03745-1.
We are writing to you in response to the article published in BMC Nephrology titled "Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study". The study provided valuable information on the use of nafamostat mesylate (NM) during continuous renal replacement therapy (CRRT) in critically ill patients. We noticed in this study that a higher dose of NM resulted in a decrease in ICU and hospital mortality. However, the underlying mechanism behind this phenomenon remains unclear. We believe exploring this further is warranted.
我们写信给您是为了回应发表在 BMC Nephrology 上的一篇题为“在危重症患者连续性肾脏替代治疗中使用甲磺酸萘莫司他的剂量：一项两中心观察性研究”的文章。该研究提供了有关在危重症患者中使用甲磺酸萘莫司他（NM）进行连续肾脏替代治疗（CRRT）的有价值的信息。我们在这项研究中注意到，较高剂量的 NM 可降低 ICU 和住院死亡率。然而，这一现象背后的潜在机制尚不清楚。我们认为进一步探索这一现象是有必要的。
Zotero 插件